Inotiv

NOTV · NASDAQ

Price unavailable right now.

No price history for this range.

About NOTV

Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. The company is headquartered in West Lafayette, Indiana and currently employs 1,945 full-time employees. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. The company operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.

Employees
1,996
Headquarters
West Lafayette, Indiana
Listed
Nov 25, 1997
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
inotiv.com

NOTV key statistics

This section is temporarily unavailable. Refresh to try again.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $3.06
Low
$1.51
High
$5.25

NOTV earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 25.8% on average.

  1. Q3 FY24: reported -$1.00 per share against an estimate of -$0.8517
  2. Q4 FY24: reported -$0.73 per share against an estimate of -$0.9282
  3. Q1 FY25: reported -$1.02 per share against an estimate of -$0.969
  4. Q2 FY25: reported -$0.44 per share against an estimate of -$0.6477
  5. Q3 FY25: reported -$0.51 per share against an estimate of -$0.5253
  6. Q4 FY25: reported -$0.25 per share against an estimate of -$0.4692
  7. Q1 FY26: reported -$0.83 per share against an estimate of -$0.6528
  8. Q2 FY26: reported -$0.94 per share against an estimate of -$0.6477

NOTV news

  • Press releaseBusiness Wire

    Inotiv Successfully Completes Financial Restructuring Process

  • Press releaseBusiness Wire

    Inotiv Announces Confirmation of Plan of Reorganization

  • Press releaseBusiness Wire

    Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Insights Ahead: Inotiv's Quarterly Earnings

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

Similar companies

Companies in the same industry as Inotiv

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.